Tandem Diabetes Care, Inc.
boothcheck covers Tandem Diabetes Care, Inc. (TNDM) but does not put one priced-in number on it: here the defensible answer is the evidence rather than a point estimate. boothcheck publishes no house fair value, target price, or buy/sell rating. Narrative composed July 11, 2026.
• Tandem runs a two-pump portfolio, the t:slim X2 and the smaller Mobi, both on its Control-IQ+ automation software now cleared for adults with type 2 diabetes; the FY2025 10-K describes it plainly: ⟦"The Company offers an insulin pump portfolio, which includes both the t:slim X2 and the Tandem Mobi. Both pumps feature Control-IQ+ technology"⟧, and supplies rather than hardware make up 54% of sales. • At $15.39 (July 10, 2026) the market pays about 1.2x revenue for a business that still loses mo
Is TNDM overvalued? See what's priced in →
263 institutional managers reported holding TNDM in 13F filings for the quarter ended 2026-03-31. 39 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 10.9M shares were sold short as of the 2026-06-15 count, about 16% of shares outstanding (4.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
TNDM's share count grew 9.1% over the past five years even with $30.00M spent on repurchases. It pays no dividend. Cash returned over the past three years: $30.00M in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at TNDM over the trailing three years: 2023: 4 buys totaling $242k; 2024: 1 buy totaling $12k; 2025: 3 buys totaling $443k. 18 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
TNDM's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | +2.8% | -42.6% |
| 2023-11-02 | -12.1% | +82.0% |
| 2024-02-22 | +6.1% | +42.2% |
| 2024-05-03 | +23.5% | -9.6% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
TNDM's latest 8-K filings: 2026-08-06 (items 2.02, 9.01); 2026-05-21 (items 3.03, 5.02, 5.07, 9.01); 2026-05-15 (items 5.02); 2026-05-07 (items 2.02, 9.01); 2026-02-27 (items 1.01, 2.03, 3.02, 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 11, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.